Lineage Cell Therapeutics, Inc. (LCTX): auditor change — Lineage Cell Therapeutics appoints Baker Tilly as auditor after Moss Adams merger

Lineage Cell Therapeutics, Inc.

Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned as auditor.
Audit Committee approved Baker Tilly as successor for fiscal year ending Dec 31, 2025.
No disagreements or reportable events occurred during the past two fiscal years or interim period.
Moss Adams' 2024 audit report was unqualified and contained no adverse opinion.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Lineage Cell Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.

Action: engagement
Auditor: Baker Tilly US, LLP

Exact text from the filing

the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Moss Adams LLP resigned as auditor of Lineage Cell Therapeutics, Inc..

Action: resignation
Auditor: Moss Adams LLP
Successor: Baker Tilly US, LLP

Exact text from the filing

In connection with the notification of the merger, Moss Adams resigned as the auditors of the Company

View on SEC.gov

Browse all auditor changes →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-083866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.